Category: Tool-products

TG6002 TG6002, multifunctional oncolytic virus A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the tumor. TG6002 aims to attack solid tumors on multiple “fronts” while avoiding the side effects of chemotherapy. This… Continue reading produits : TG6002

TG4001 TG4001 is a therapeutic vaccine designed to express HPV-16 antigens TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens. TG4001 is being evaluated in a Phase II study… Continue reading produits : TG4001

AstraZeneca Transgene and AstraZeneca have entered into a collaboration agreement under which Transgene designs five innovative oncolytic viruses based on the Invir.IO™ platform. AstraZeneca can exercise an option on each of these candidates.

TG6050 Induce an immune response against tumors resistant to available treatments TG6050 is an oncolytic virus that has been engineered to express human IL-12 and an anti-CTLA4 antibody. TG6050 has been designed to be administered intravenously. By selectively targeting tumor cells and expressing IL-12 and an anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected… Continue reading produits : TG6050

BT-001 BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. This novel immunotherapy approach has been designed to be highly targeted and is based on the patented viral backbone (VVcop TK-RR-). Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was… Continue reading produits : BT-001 teaser

TG4001 Target HPV-induced cancers (HPV-16, E6 & E7 + IL-2) TG4001, an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens. We have selected typical papillomavirus sequences that code for these antigens… Continue reading produits : TG4001 teaser

TG4050 One patient, one cancer, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities, together with NEC. Each treatment is based on an optimized viral vector, that is customized and manufactured for each patient. It integrates the most relevant tumor targets (patient-specific… Continue reading produits : TG4050 teaser

Product Indication Collaboration Discovery Phase I Phase II INDIVIDUALIZED NEOANTIGEN CANCER VACCINES TG4050 Head and neck cancers (adjuvant) Other indication SHARED ANTIGENS CANCER VACCINES TG4001   Anogenital HPV+ cancers   Internal Shared driver mutations       ONCOLYTIC VIRUSES (OV) TG6050 Lung cancer (IV*)     BT-001 Solid tumors (IT*)   Internal   Synthetic OV… Continue reading pipeline